NBS NeoStem, Inc. Announces the Redemption of the

New Post Public Reply Private Reply Replies (0) Message Board

Oct 17, 2012 at 9:44 AM

NBS >>> NeoStem, Inc. Announces the Redemption of the Outstanding 7% Series E Preferred Stock

2012-10-17 07:30 ET - News Release

NEW YORK, Oct. 17, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that it will redeem all outstanding shares of its Series E 7% Senior Convertible Preferred Stock ("Series E Preferred Stock").

On October 10, 2012, the Company gave notice to its Series E Preferred Stockholders that it is redeeming all of the outstanding shares of Series E Preferred Stock for an aggregate redemption price of $3.4 million, $2.5 million of which was funded by money placed into escrow when the Series E Preferred stock was issued in November 2010.

"We are pleased that we have been able to redeem this $10 million investment in full over a two year period. Equal to our focus on cell therapy product development and expanding our PCT contract development and manufacturing operations, we are committed to improving our balance sheet. Through the redemption of the Series E Preferred Stock, we will remove a significant overhang and simplify NeoStem's capital structure. The redemption of the Series E Preferred Stock is another example of a step taken by us to improve Common Stockholder value," said Dr. Robin Smith, Chairman and CEO of NeoStem. "We look forward to continued execution on our near term business strategy, including the forthcoming closing of the divestiture of our Erye China pharmaceutical subsidiary."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SimpliTrain's Momentum in LMS Market Heating Up

SimpliTrain Finds its Groove in the LMS Arena Out here in Delray Beach, SimpliTrain's making waves in the Learning Management System (LMS) market, recently snagging the 'Pervasive Player' tag from MarketsandMarkets' 360Quadrants platform. This cloud-based learning powerhouse ain't just playing around; they're doubling down with expansion into AI and other fancy tech bits...

ASU Teams Up for National Manufacturing Workforce Push

ASU's Role in Reviving American Manufacturing The Foundry School is a big hit for Arizona State University (ASU) as it joins hands with seven other top-tier universities under the U.S. Departments of State and Labor's initiative. This project is all about sculpting the future players of American manufacturing. In a scene highlighted by the Vice President and girded by...

Carles Puyol Joins Midea at IFA 2026, Celebrating Unity

Leadership, Innovation, and Soccer Collide in Berlin When you’ve got a Barcelona legend like Carles Puyol gracing an event, it's more than just fanfare. This time around, Puyol made waves at Midea's stand during IFA 2026 in Berlin, signaling a strategic power move for both Midea and FC Barcelona. We're talking about a scene where tech innovation meets world-class...

AARP New York Promotes Affordable 'Staycation' Experiences

Exploring New York Without Breaking the Bank Tough times call for creative solutions, and AARP New York is on the ball. With travel costs soaring and many older New Yorkers scrimping to make ends meet, the 'Staycation' campaign steps in with an offer too good to pass up: uncovering the gems of New York right under our noses without shelling out hefty sums. The plan? Turn...

Tetragon Completes $50M Tender Offer; Shares Prorated

Unpacking Tetragon’s $50 Million Dutch Auction Move If you comb through the smoke-filled corridors of finance, you'll find the name Tetragon Financial Group pacing the latest tender offer rounds. They danced their way through a $50 million 'modified Dutch auction,' snapping up non-voting shares with a kind of ruthless efficiency that only seasoned market players can...

Hyundai's Revolutionary US Steel Mill Set for 2029 Rollout

Hyundai's Major Steel Move: A Multibillion-Dollar Stake The steel industry scene in the U.S. just got a lot hotter with Hyundai's announcement of a $5.8 billion Electric Arc Furnace-based integrated steel mill in Louisiana. This game-changing project isn’t just a headline; it’s a concrete step towards beefing up the U.S. manufacturing backbone. Talk about...

Woodland Direct Expands West with Reno Facility

Woodland Direct Takes a Bold Step Westward It's no small feat when a company's growing pains turn into growing gains, yet that's exactly what Woodland Direct has managed to pull off with their latest expansion strategy. The Auburn Hills-based e-commerce juggernaut, synonymous with high-quality fire products, just cut the ribbon on a sparkling new 47,000-square-foot...

Megan Holdings Investors Face Deadline for Class Action

Forgive my bluntness, but if you've been snoozing on your Megan Holdings Limited (NASDAQ:MGN) shares, it's time to wake up and smell the lawsuit papers. They're flying around faster than news at a market crash. If you snagged those shares between September 26, 2025, and March 25, 2026, or got in during the IPO on September 26, 2025, here's the deal: the deadline looms on...

Pudu Robotics Showcases Expansive Portfolio at IFA 2026

Robotics in the Spotlight: Pudu's Grand European Entry Well, you don't see this every day—Pudu Robotics, a name riding high in the robotics sphere, is strutting its stuff over at IFA 2026 in Berlin. This ain't just a teaser, folks. They're unloading the whole toolkit, diving head-first into the European market. From gears turning in service delivery bots to industrial...

Powder River Crude's Open Season: Strategic Move

Powder River Crude Services Drives Into Wyoming Every now and then, a player's got to lay down their cards early, and Powder River Crude Services is doing just that with their open season announcement. Anyone keeping an eye on the crude oil transport game will want to watch how this proposed pipeline project unfolds. Slated to stretch from Converse County to Douglas,...